Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sentinel node detection with technetium-99m albumin nanocolloid and indocyanine green in early-stage epithelial ovarian cancer
2023-505667-37-00Phase 2Completed
- Sponsor
- IDIBAPS
- Start
- Sep 2023
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of technetium Tc 99m macroaggregated albumin and indocyanine green in epithelial ovarian cancer (EOC), sponsored by IDIBAPS. Primary endpoint: Global detection rate of sentinel lymph node. Started Sep 2023; status: completed.
02
Drugs
technetium Tc 99m macroaggregated albuminindocyanine green
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2023-505667-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505667-37-00.